Sedana Medical’s nomination committee appointed
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 22, 2018, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.
Sedana Medical's Nomination Committee for the 2019 Annual General Meeting consists of:
- Thomas Eklund, Chairman of the Board
- Sten Gibeck, Board member
- Karl Tobieson, appointed by Linc AB
- Ola Magnusson, Board member – appointed by Magiola AB
Karl Tobieson is appointed chairman of the Nomination Committee.
The Nomination Committee represents 27.2 per cent of all voting rights in the company as of September 30, 2018.
The Nomination Committee shall submit proposals for resolution by the 2019 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.
The Annual General Meeting of Sedana Medical will be held May 28, 2019.
Shareholders wishing to submit proposals to Sedana Medical’s Nomination Committee can do so by e-mail to email@example.com by January 31, 2019.
For additional information, please contact:
Nomination Committee Chairman, Karl Tobieson
Phone: +46 70 935 85 74
Sedana Medical is listed on Nasdaq First North in Stockholm
and Erik Penser Bank (+46 8 463 83 00) is certified adviser to Sedana Medical.
This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 3 December 2018 at 17:00 pm (CET).
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane)
Sedana Medical has direct sales in the Nordic countries, Germany, France, Great Britain and Spain as well as external distributors in the rest of Europe, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.